drugset / Trial / NCT04889690
Study of Multiple Doses of Danicopan in Healthy Participants
Phase 1
Completed
45 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This was a multiple ascending dose, randomized, double-blind study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants. Four different doses (75 milligrams \[mg\], 200 mg, 500 mg, 800 mg) and dose-matched placebo were administered under fasted conditions.
Timeline
- Start
- 2016-05-21
- Primary completion
- 2017-01-11
- Completion
- 2017-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danicopan | Small molecule | 75 mg | — |
| Subject | Danicopan | Small molecule | 200 mg | — |
| Subject | Danicopan | Small molecule | 500 mg | — |
| Subject | Danicopan | Small molecule | 800 mg | — |
Indications
No indication recorded.